135 related articles for article (PubMed ID: 7562923)
1. Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity.
Cynamon MH; Gimi R; Gyenes F; Sharpe CA; Bergmann KE; Han HJ; Gregor LB; Rapolu R; Luciano G; Welch JT
J Med Chem; 1995 Sep; 38(20):3902-7. PubMed ID: 7562923
[TBL] [Abstract][Full Text] [Related]
2. Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters.
Bergmann KE; Cynamon MH; Welch JT
J Med Chem; 1996 Aug; 39(17):3394-400. PubMed ID: 8765523
[TBL] [Abstract][Full Text] [Related]
3. Antimycobacterial activity of a series of pyrazinoic acid esters.
Cynamon MH; Klemens SP; Chou TS; Gimi RH; Welch JT
J Med Chem; 1992 Apr; 35(7):1212-5. PubMed ID: 1560435
[TBL] [Abstract][Full Text] [Related]
4. Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of Mycobacterium tuberculosis and Other Naturally Resistant Mycobacteria In Vitro and Ex Vivo within Macrophages.
Pires D; Valente E; Simões MF; Carmo N; Testa B; Constantino L; Anes E
Antimicrob Agents Chemother; 2015 Dec; 59(12):7693-9. PubMed ID: 26438493
[TBL] [Abstract][Full Text] [Related]
5. In vitro antimycobacterial activities of pyrazinamide analogs.
Yamamoto S; Toida I; Watanabe N; Ura T
Antimicrob Agents Chemother; 1995 Sep; 39(9):2088-91. PubMed ID: 8540721
[TBL] [Abstract][Full Text] [Related]
6. [In vitro antimycobacterial activities of pyrazinamide analogs: results of screening tests].
Yamamoto S; Toida I; Watanabe N; Ura T
Kekkaku; 1996 Mar; 71(3):253-8. PubMed ID: 8901227
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and antimycobacterial activity of pyrazine and quinoxaline derivatives.
Seitz LE; Suling WJ; Reynolds RC
J Med Chem; 2002 Dec; 45(25):5604-6. PubMed ID: 12459027
[TBL] [Abstract][Full Text] [Related]
8. Antimycobacterial evaluation of pyrazinoic acid reversible derivatives.
Dolezal M; Kesetovic D; Zitko J
Curr Pharm Des; 2011; 17(32):3506-14. PubMed ID: 22074423
[TBL] [Abstract][Full Text] [Related]
9. Salicylanilide pyrazinoates inhibit in vitro multidrug-resistant Mycobacterium tuberculosis strains, atypical mycobacteria and isocitrate lyase.
Krátký M; Vinšová J; Novotná E; Stolaříková J
Eur J Pharm Sci; 2014 Mar; 53():1-9. PubMed ID: 24333643
[TBL] [Abstract][Full Text] [Related]
10. Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide.
Speirs RJ; Welch JT; Cynamon MH
Antimicrob Agents Chemother; 1995 Jun; 39(6):1269-71. PubMed ID: 7574514
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and antimycobacterial evaluation of pyrazinamide derivatives with benzylamino substitution.
Zitko J; Paterová P; Kubíček V; Mandíková J; Trejtnar F; Kuneš J; Doležal M
Bioorg Med Chem Lett; 2013 Jan; 23(2):476-9. PubMed ID: 23237840
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and antimycobacterial evaluation of N-substituted 3-aminopyrazine-2,5-dicarbonitriles.
Zitko J; Jampílek J; Dobrovolný L; Svobodová M; Kuneš J; Doležal M
Bioorg Med Chem Lett; 2012 Feb; 22(4):1598-601. PubMed ID: 22281187
[TBL] [Abstract][Full Text] [Related]
13. Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli.
Zimhony O; Vilchèze C; Arai M; Welch JT; Jacobs WR
Antimicrob Agents Chemother; 2007 Feb; 51(2):752-4. PubMed ID: 17101678
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, antimycobacterial and antifungal evaluation of 3-arylaminopyrazine-2,5-dicarbonitriles.
Palek L; Dvorák J; Svobodová M; Buchta V; Jampílek J; Dolezal M
Arch Pharm (Weinheim); 2008 Jan; 341(1):61-5. PubMed ID: 18072243
[TBL] [Abstract][Full Text] [Related]
15. Antimycobacterial N-pyridinylsalicylamides, isosters of salicylamides.
Waisser K; Drazková K; Kunes J; Klimesová V; Kaustová J
Farmaco; 2004 Aug; 59(8):615-25. PubMed ID: 15262531
[TBL] [Abstract][Full Text] [Related]
16. Mycobacterium canettii is intrinsically resistant to both pyrazinamide and pyrazinoic acid.
Feuerriegel S; Köser CU; Richter E; Niemann S
J Antimicrob Chemother; 2013 Jun; 68(6):1439-40. PubMed ID: 23447141
[No Abstract] [Full Text] [Related]
17. Antimycobacterial activity of salicylanilide benzenesulfonates.
Krátký M; Vinšová J; Rodriguez NG; Stolaříková J
Molecules; 2012 Jan; 17(1):492-503. PubMed ID: 22222908
[TBL] [Abstract][Full Text] [Related]
18. Combating highly resistant emerging pathogen Mycobacterium abscessus and Mycobacterium tuberculosis with novel salicylanilide esters and carbamates.
Baranyai Z; Krátký M; Vinšová J; Szabó N; Senoner Z; Horváti K; Stolaříková J; Dávid S; Bősze S
Eur J Med Chem; 2015 Aug; 101():692-704. PubMed ID: 26210507
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, antimycobacterial activity and in vitro cytotoxicity of 5-chloro-N-phenylpyrazine-2-carboxamides.
Zitko J; Servusová B; Paterová P; Mandíková J; Kubíček V; Kučera R; Hrabcová V; Kuneš J; Soukup O; Doležal M
Molecules; 2013 Dec; 18(12):14807-25. PubMed ID: 24317522
[TBL] [Abstract][Full Text] [Related]
20. Antimycobacterial activity of pyrazinoate prodrugs in replicating and non-replicating Mycobacterium tuberculosis.
Segretti ND; Simões CK; Corrêa MF; Felli VMA; Miyata M; Cho SH; Franzblau SG; Fernandes JPDS
Tuberculosis (Edinb); 2016 Jul; 99():11-16. PubMed ID: 27449999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
